PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds
Key Highlights
- ➤NantWorks exercised warrants for 17,699,115 PDSB shares at $0.22 each
- ➤Warrant exercise generated approximately $3.9 million in gross proceeds
- ➤PDS Biotech will fund PDS0301 Phase 3 preparation and PDS0101 partnerships
- ➤September 2026 private placement initially generated approximately $11.3 million
PRINCETON, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced NantWorks has exercised its outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at an exercise price of $0.22 per share. The gross proceeds to the Company from the exercise of existing warrants were approximately $3.9 million.
The Company intends to use the net proceeds from the warrant exercise, together with the net proceeds from the September 2026 private placement, to support the advancement of PDS0301 toward a Phase 3 trial in metastatic colorectal cancer, as well as the Company’s partnership strategy for PDS0101 and general corporate purposes.
Get started
Create a free account to read the full story.